Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA – Get Rating) saw a significant decrease in short interest during the month of April. As of April 30th, there was short interest totalling 77,800 shares, a decrease of 14.5% from the April 15th total of 91,000 shares. Based on an average daily volume of 1,100,000 shares, the short-interest ratio is presently 0.1 days.
Sonoma Pharmaceuticals stock opened at $3.92 on Wednesday. The firm has a market capitalization of $12.14 million, a price-to-earnings ratio of -1.49 and a beta of 1.01. Sonoma Pharmaceuticals has a fifty-two week low of $2.55 and a fifty-two week high of $13.36. The stock’s fifty day moving average is $3.17 and its two-hundred day moving average is $4.00.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Dimensional Fund Advisors LP boosted its stake in shares of Sonoma Pharmaceuticals by 33.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 15,006 shares of the company’s stock valued at $68,000 after acquiring an additional 3,723 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Sonoma Pharmaceuticals during the third quarter valued at $88,000. Finally, Geode Capital Management LLC boosted its stake in shares of Sonoma Pharmaceuticals by 22.2% during the third quarter. Geode Capital Management LLC now owns 36,878 shares of the company’s stock valued at $205,000 after acquiring an additional 6,697 shares during the last quarter. 5.75% of the stock is currently owned by institutional investors and hedge funds.
Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis.
- Get a free copy of the StockNews.com research report on Sonoma Pharmaceuticals (SNOA)
- Roku Stock is Repricing and Resetting Itself
- The Institutions Are Capping Gains In Take-Two Interactive
- Walmart’s “Everyday Low Prices” Gets Burned By Inflation
- VMWare Inc: Strong Revenues and Excellent Potential
- Beware The Rebound In Home Depot
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.